Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Macaya, Douoguih"'
Autor:
Daniela Manno, Philip Ayieko, David Ishola, Muhammed O. Afolabi, Baimba Rogers, Frank Baiden, Alimamy Serry-Bangura, Osman M. Bah, Brian Köhn, Ibrahim Swaray, Kwabena Owusu-Kyei, Godfrey T. Otieno, Dickens Kowuor, Daniel Tindanbil, Elizabeth Smout, Cynthia Robinson, Babajide Keshinro, Julie Foster, Katherine Gallagher, Brett Lowe, Macaya Douoguih, Bailah Leigh, Brian Greenwood, Deborah Watson-Jones
Publikováno v:
Emerging Infectious Diseases, Vol 28, Iss 3, Pp 734-738 (2022)
We explored the association of Ebola virus antibody seropositivity and concentration with potential risk factors for infection. Among 1,282 adults and children from a community affected by the 2014–2016 Ebola outbreak in Sierra Leone, 8% were serop
Externí odkaz:
https://doaj.org/article/2254071766d6435e89e08cf0d179f013
Autor:
Jerald, Sadoff, Glenda, Gray, An, Vandebosch, Vicky, Cárdenas, Georgi, Shukarev, Beatriz, Grinsztejn, Paul A, Goepfert, Carla, Truyers, Hein, Fennema, Bart, Spiessens, Kim, Offergeld, Gert, Scheper, Kimberly L, Taylor, Merlin L, Robb, John, Treanor, Dan H, Barouch, Jeffrey, Stoddard, Martin F, Ryser, Mary A, Marovich, Kathleen M, Neuzil, Lawrence, Corey, Nancy, Cauwenberghs, Tamzin, Tanner, Karin, Hardt, Javier, Ruiz-Guiñazú, Mathieu, Le Gars, Hanneke, Schuitemaker, Johan, Van Hoof, Frank, Struyf, Macaya, Douoguih, Marcus, Zervos
Publikováno v:
New England Journal of Medicine. 384:2187-2201
The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation.In an internation
Autor:
Zacchaeus Anywaine, Houreratou Barry, Omu Anzala, Gaudensia Mutua, Sodiomon B. Sirima, Serge Eholie, Hannah Kibuuka, Christine Bétard, Laura Richert, Christine Lacabaratz, M. Juliana McElrath, Stephen C. De Rosa, Kristen W. Cohen, Georgi Shukarev, Michael Katwere, Cynthia Robinson, Auguste Gaddah, Dirk Heerwegh, Viki Bockstal, Kerstin Luhn, Maarten Leyssen, Rodolphe Thiébaut, Macaya Douoguih, on behalf of the EBL2002 Study group
Publikováno v:
PLoS Medicine
PLoS Medicine, Public Library of Science, 2022, 19 (1), pp.e1003865. ⟨10.1371/journal.pmed.1003865⟩
PLoS Medicine, Vol 19, Iss 1 (2022)
PLoS Medicine, 2022, 19 (1), pp.e1003865. ⟨10.1371/journal.pmed.1003865⟩
PLoS Medicine, Vol 19, Iss 1, p e1003865 (2022)
PLoS Medicine, Public Library of Science, 2022, 19 (1), pp.e1003865. ⟨10.1371/journal.pmed.1003865⟩
PLoS Medicine, Vol 19, Iss 1 (2022)
PLoS Medicine, 2022, 19 (1), pp.e1003865. ⟨10.1371/journal.pmed.1003865⟩
PLoS Medicine, Vol 19, Iss 1, p e1003865 (2022)
Background Reoccurring Ebola outbreaks in West and Central Africa have led to serious illness and death in thousands of adults and children. The objective of this study was to assess safety, tolerability, and immunogenicity of the heterologous 2-dose
Autor:
Georgi Shukarev, Helen R Wagstaffe, Jeroen N Stoop, Viki Bockstal, Eleanor M. Riley, Kerstin Luhn, Matthew D. Snape, Andrew J. Pollard, Martin R. Goodier, Macaya Douoguih, Elizabeth A. Clutterbuck
Publikováno v:
The Journal of Infectious Diseases
Wagstaffe, H R, Clutterbuck, E A, Bockstal, V, Stoop, J N, Luhn, K, Douoguih, M, Shukarev, G, Snape, M D, Pollard, A J, Riley, E M & Goodier, M R 2019, ' Antibody-Dependent Natural Killer Cell Activation after Ebola Vaccination ', The Journal of Infectious Diseases . https://doi.org/10.1093/infdis/jiz657
Wagstaffe, H R, Clutterbuck, E A, Bockstal, V, Stoop, J N, Luhn, K, Douoguih, M, Shukarev, G, Snape, M D, Pollard, A J, Riley, E M & Goodier, M R 2019, ' Antibody-Dependent Natural Killer Cell Activation after Ebola Vaccination ', The Journal of Infectious Diseases . https://doi.org/10.1093/infdis/jiz657
Background Antibody Fc-mediated functions, such as antibody-dependent cellular cytotoxicity, contribute to vaccine-induced protection against viral infections. Fc-mediated function of anti-Ebola glycoprotein (GP) antibodies suggest that Fc-dependent
Autor:
Hilary S. Whitworth, Pontiano Kaleebu, George PrayGod, Macaya Douoguih, Saidi Kapiga, Deborah Watson-Jones, Dickson Anumendem, Kerstin Luhn, Samuel E. Kalluvya, Cynthia Robinson, Georgi Shukarev, Daniela Manno, Viki Bockstal, Zacchaeus Anywaine, Heiner Grosskurth
Publikováno v:
The Journal of Infectious Diseases
Background Ebola vaccine development was accelerated in response to the 2014 Ebola virus infection outbreak. This phase 1 study (VAC52150EBL1004) assessed safety, tolerability, and immunogenicity of heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccina
Autor:
Hanneke Schuitemaker, Jerald C. Sadoff, Gert Scheper, Jeroen Stoop, Emmanuel Cormier, Pierre Van Damme, Isabel Leroux-Roels, Johan Van Hoof, Anne Marit de Groot, Wim Van Damme, Frank Struyf, Sarah Tete, Carla Truyers, Mathieu Le Gars, Jenny Hendriks, William T. Smith, Murray Kimmel, Dirk Heerwegh, Kristen W. Cohen, Georgi Shukarev, Jan de Hoon, M Juliana McElrath, Macaya Douoguih, Dan H. Barouch, Stephen C De Rosa, Pieter-Jan Berghmans, Kathryn E. Stephenson
Publikováno v:
The New England Journal of Medicine
New England Journal of Medicine
NEW ENGLAND JOURNAL OF MEDICINE
The New England journal of medicine
New England Journal of Medicine
NEW ENGLAND JOURNAL OF MEDICINE
The New England journal of medicine
BACKGROUND: Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinan
Autor:
Kerstin Luhn, Neil Goldstein, Cynthia Robinson, Auguste Gaddah, Viki Bockstal, Stephan Bart, Benoit Callendret, Macaya Douoguih
Publikováno v:
The Journal of infectious diseases. 226(4)
Background This phase 1 placebo-controlled study assessed the safety and immunogenicity of 2-dose regimens of Ad26.ZEBOV (adenovirus serotype 26 [Ad26]) and MVA-BN-Filo (modified vaccinia Ankara [MVA]) vaccines with booster vaccination at day 360. Me
Autor:
Jeroen N Stoop, Macaya Douoguih, Georgi Shukarev, Viki Bockstal, Matthew D. Snape, Helen R Wagstaffe, Elizabeth A. Clutterbuck, Eleanor M. Riley, Andrew J. Pollard, Kerstin Luhn, Martin R. Goodier
Publikováno v:
The Journal of Clinical Investigation
Journal of Clinical Investigation
Wagstaffe, H R, Clutterbuck, E A, Bockstal, V, Stoop, J N, Luhn, K, Douoguih, M, Shukarev, G, Snape, M D, Pollard, A J, Riley, E & Goodier, M R 2020, ' Ebola virus glycoprotein stimulates IL-18 dependent natural killer cell responses ', Journal of Clinical Investigation, vol. 130, no. 7, pp. 3936-3946 . https://doi.org/10.1172/JCI132438
Journal of Clinical Investigation
Wagstaffe, H R, Clutterbuck, E A, Bockstal, V, Stoop, J N, Luhn, K, Douoguih, M, Shukarev, G, Snape, M D, Pollard, A J, Riley, E & Goodier, M R 2020, ' Ebola virus glycoprotein stimulates IL-18 dependent natural killer cell responses ', Journal of Clinical Investigation, vol. 130, no. 7, pp. 3936-3946 . https://doi.org/10.1172/JCI132438
BACKGROUND NK cells are activated by innate cytokines and viral ligands to kill virus-infected cells. These functions are enhanced during secondary immune responses and after vaccination by synergy with effector T cells and virus-specific antibodies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81181ba11dd89380301e8cad8cf648fe
Autor:
Kerstin Luhn, Dickson Anumendem, Gaudensia Mutua, Omu Anzala, Cynthia Robinson, Viki Bockstal, Macaya Douoguih
Publikováno v:
The Journal of Infectious Diseases
Background During the 2014 West African Ebola outbreak, Ebola vaccine development was accelerated. The phase 1 VAC52150EBL1003 study was performed to investigate 2-dose heterologous vaccination with Ad26.ZEBOV and MVA-BN-Filo in an African population
Autor:
Matthew D. Snape, Merryn Voysey, Kerstin Luhn, Macaya Douoguih, Georgi Shukarev, Rebecca L Winslow, Iain D. Milligan
Publikováno v:
JAMA
The Ebola virus vaccine strategies evaluated by the WHO in response to the recent outbreak in West Africa included a heterologous prime/boost schedule of the adenovirus type 26 vector vaccine encoding Ebola virus glycoprotein (Ad26.ZEBOV) and the mod